JOP20210058A1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents

مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Info

Publication number
JOP20210058A1
JOP20210058A1 JOP/2021/0058A JOP20210058A JOP20210058A1 JO P20210058 A1 JOP20210058 A1 JO P20210058A1 JO P20210058 A JOP20210058 A JO P20210058A JO P20210058 A1 JOP20210058 A1 JO P20210058A1
Authority
JO
Jordan
Prior art keywords
methods
disorders
formula
monoacylglycerol lipase
modulators
Prior art date
Application number
JOP/2021/0058A
Other languages
English (en)
Inventor
Chaofeng Huang
Gang Chen
Brian Ngo Laforteza
Emma Helen Southgate
Michael K Ameriks
Suchitra Ravula
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20210058A1 publication Critical patent/JOP20210058A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

مركبات ملتحمة من الصيغة (I) والصيغة (II) وتركيبات صيدلانية تحتوي عليها وطرق صنعها، وأساليب استخدامها بما في ذلك وسائل علاج الحالات المرضية والاضطرابات والظروف المرتبطة بتعديل ليباز أُحادِيُّ الجلِيسِريد (MGL)، مثل تلك المرتبطة بالألم، الاضطرابات النفسية، الاضطرابات العصبية (بما في ذلك، على سبيل المثال لا الحصر، الاضطراب الاكتئابي الرئيسي، والاكتئاب المقاوم للعلاج، والاكتئاب الناتج عن القلق، والاضطراب ثنائي القطب)، والسرطانات وأمراض العيون. و ؛ حيث يتم تعريف R1، وR2، وR2a، وR3، وR3a، وR4، وR4a هنا بهذه الوثيقة.
JOP/2021/0058A 2018-09-28 2019-09-27 مُعدلات ليباز أُحادِيُّ الجلِيسِريد JOP20210058A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28
PCT/IB2019/058240 WO2020065613A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
JOP20210058A1 true JOP20210058A1 (ar) 2021-03-24

Family

ID=68109428

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0058A JOP20210058A1 (ar) 2018-09-28 2019-09-27 مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Country Status (23)

Country Link
US (3) US20200102303A1 (ar)
EP (1) EP3856178A1 (ar)
JP (1) JP2022502424A (ar)
KR (1) KR20210069080A (ar)
CN (1) CN113164459A (ar)
AU (1) AU2019350624A1 (ar)
BR (1) BR112021005896A2 (ar)
CA (1) CA3111380A1 (ar)
CL (1) CL2021000757A1 (ar)
CO (1) CO2021003944A2 (ar)
CR (1) CR20210153A (ar)
EA (1) EA202190886A1 (ar)
EC (1) ECSP21021381A (ar)
IL (1) IL281812A (ar)
JO (1) JOP20210058A1 (ar)
MA (1) MA53721A (ar)
MX (1) MX2021003737A (ar)
NI (1) NI202100023A (ar)
PE (1) PE20211773A1 (ar)
PH (1) PH12021550659A1 (ar)
SG (1) SG11202102281VA (ar)
TW (1) TW202028198A (ar)
WO (1) WO2020065613A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
TW202028198A (zh) 2018-09-28 2020-08-01 比利時商健生藥品公司 單醯基丙三醇脂酶調節劑
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
MX2022003819A (es) * 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
WO2021191359A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
AR127955A1 (es) 2021-12-16 2024-03-13 Hoffmann La Roche Nuevos compuestos heterocíclicos

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
JP2008510810A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合トリアゾール誘導体
WO2006080884A1 (en) 2005-01-27 2006-08-03 Astrazeneca Ab Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
PE20090418A1 (es) 2007-06-21 2009-04-18 Schering Corp Derivados de guanina policiclicos y sus metodos de uso
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
CN102066360B (zh) 2008-04-22 2013-10-30 詹森药业有限公司 喹啉或异喹啉取代的p2x7拮抗剂
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
EP2421535A1 (en) * 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
WO2010125102A1 (en) 2009-04-29 2010-11-04 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
JP5822911B2 (ja) 2010-04-02 2015-11-25 ユーロスクリーン エス．エー． 新規のｎｋ−３受容体選択的アンタゴニスト化合物、医薬組成物、及びｎｋ−３受容体媒介疾患における使用方法
US20110252717A1 (en) 2010-04-16 2011-10-20 Graf Fernandez Rodrigo Foldable structures for a construction
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
KR20150074193A (ko) 2012-11-01 2015-07-01 인사이트 코포레이션 Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP6273621B2 (ja) 2012-12-21 2018-02-07 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
SG11201506245QA (en) 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
RU2667509C2 (ru) 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
EP2970283B1 (en) 2013-03-14 2020-11-11 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
CN105209449B (zh) 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
EP2989103B1 (en) 2013-03-29 2019-02-20 Ogeda Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
CA2921881A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
NZ730334A (en) 2014-09-11 2023-01-27 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
TW202028198A (zh) 2018-09-28 2020-08-01 比利時商健生藥品公司 單醯基丙三醇脂酶調節劑
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
WO2021191359A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Also Published As

Publication number Publication date
CA3111380A1 (en) 2020-04-02
WO2020065613A1 (en) 2020-04-02
CR20210153A (es) 2021-05-11
US20230145249A1 (en) 2023-05-11
PH12021550659A1 (en) 2022-02-21
IL281812A (en) 2021-05-31
US20200102303A1 (en) 2020-04-02
ECSP21021381A (es) 2021-04-29
EA202190886A1 (ru) 2021-09-07
SG11202102281VA (en) 2021-04-29
US11820766B2 (en) 2023-11-21
TW202028198A (zh) 2020-08-01
CN113164459A (zh) 2021-07-23
MA53721A (fr) 2021-09-15
US20220332713A1 (en) 2022-10-20
EP3856178A1 (en) 2021-08-04
BR112021005896A2 (pt) 2021-07-27
MX2021003737A (es) 2021-05-14
PE20211773A1 (es) 2021-09-08
JP2022502424A (ja) 2022-01-11
CL2021000757A1 (es) 2021-08-27
NI202100023A (es) 2021-09-07
AU2019350624A1 (en) 2021-03-18
CO2021003944A2 (es) 2021-04-19
KR20210069080A (ko) 2021-06-10

Similar Documents

Publication Publication Date Title
PH12021550659A1 (en) Monoacylglycerol lipase modulators
MX2021003661A (es) Moduladores de la monoacilglicerol lipasa.
JOP20220180A1 (ar) مُعدلات ليباز أُحادِيُّ الجلِيسِريد
MX2022011902A (es) Moduladores de la monoacilglicerol lipasa.
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
PH12015502001A1 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX2022001181A (es) Inhibidores de kif18a.
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MX366855B (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
CO2021011919A2 (es) Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes
JO3569B1 (ar) مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها
BR112022019155A2 (pt) Aril piperidinas como moduladores da monoacilglicerol lipase
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
TN2020000160A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
JOP20200272A1 (ar) مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية
EA201992127A1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
MX2023003240A (es) Moduladores de monoacilglicerol lipasa de ciclobutilamida.
MX2021009383A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2022000841A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.